title: Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.
abstract: BACKGROUND
  Long-term survival of patients with metastatic colorectal cancer has been achieved only in patients who underwent complete resection of metastases. Such surgery could be performed in a greater proportion of patients if effective chemotherapy could downstage previously unresectable metastases. This approach has been limited by the low tumor response rate achieved with conventional chemotherapy.
  
  
  OBJECTIVE
  We studied the outcome of patients with initially unresectable liver metastases from colorectal cancer treated with a three-drug chemotherapy regimen followed by liver metastases surgery whenever possible.
  
  
  METHODS
  From March 1988 to June 1994, 151 patients with colorectal liver metastases were considered initially unresectable because of large tumor size (> 5 cm), multinodular (> 4) or ill-located metastases. All patients received fully ambulatory chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin (chronotherapy in 83% of them). They were periodically reassessed for surgery by a joint medico-surgical team.
  
  
  RESULTS
  In 151 patients, the size of liver metastases decreased by > 50% in 89 patients (59%) and median overall survival was 24 months (95% confidence interval (95% CI): 19-28 months), with 28% surviving at five years (20%-35%). Surgery with curative intent was attempted in 77 patients (51%), complete resection of liver metastases was achieved in 58 patients (38%). The median survival of the 77 operated patients was 48 months (25-71), with a five-year survival rate of 50% (38-61).
  
  
  CONCLUSIONS
  This new strategy of combining effective chemotherapy with surgery apparently altered the natural history of unresectable colorectal cancer metastases.
authors.affiliation: Centre de Chronothérapie, Fédération des Maladies Sanguines Immunitaires et Tumorales, Hôpital Paul Brousse, Villejuif, France.
authors.forename: S
authors.initials: S
authors.lastname: Giacchetti
authors.forename: M
authors.initials: M
authors.lastname: Itzhaki
authors.forename: G
authors.initials: G
authors.lastname: Gruia
authors.forename: R
authors.initials: R
authors.lastname: Adam
authors.forename: R
authors.initials: R
authors.lastname: Zidani
authors.forename: F
authors.initials: F
authors.lastname: Kunstlinger
authors.forename: S
authors.initials: S
authors.lastname: Brienza
authors.forename: E
authors.initials: E
authors.lastname: Alafaci
authors.forename: F
authors.initials: F
authors.lastname: Bertheault-Cvitkovic
authors.forename: C
authors.initials: C
authors.lastname: Jasmin
authors.forename: M
authors.initials: M
authors.lastname: Reynes
authors.forename: H
authors.initials: H
authors.lastname: Bismuth
authors.forename: J L
authors.initials: JL
authors.lastname: Misset
authors.forename: F
authors.initials: F
authors.lastname: Lévi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D019454:Chronotherapy; D015179:Colorectal Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011379:Prognosis; D012189:Retrospective Studies; D017741:Survivors
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil